NASDAQ: ATHE - Alterity Therapeutics Limited

Altı ay boyunca karlılık: -24.08%
Sektör: Healthcare

Promosyon programı Alterity Therapeutics Limited

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.

Daha fazla ayrıntı
It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

Цена ао 1.45
Выручка 0.000109
EBITDA -0.0127
P/S 177.92
P/BV 1.17
EV/EBITDA -0.3872
Сайт https://alteritytherapeutics.com
ISIN US02155X1063
Число акций ао 2.42784 млрд
Валюта usd
IPO date 2002-09-05
Sector Health Care
Industry Biotechnology
Валюта отчета aud
Günlük fiyat değişimi: +1.4% (1.43)
Haftalık fiyat değişimi: +16.94% (1.24)
Aylık fiyat değişimi: +15.08% (1.26)
3 ayda fiyat değişimi: -19.04% (1.791)
Altı ayda fiyat değişimi: -24.08% (1.91)
Yıllık fiyat değişimi: -43.58% (2.57)
3 yılda fiyat değişimi: +13.28% (1.28)
5 yılda fiyat değişimi: +27.19% (1.14)
Yılbaşından bu yana fiyat değişimi: -35.56% (2.25)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 3895.96 1
P/BV 445.47 1
P/E 0 0
EV/EBITDA -668.18 0
Toplam: 0.625

Yeterlik

İsim Anlam Seviye
ROA, % -50.54 0
ROE, % -60.52 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.0139 10
Toplam: 9.4

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 2303.26 10
karlılık Ebitda, % 19.72 3
karlılık EPS, % -55.57 0
Toplam: 4.2
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Morgan Stanley 51485 0.7
Bank of Montreal/Can/ 14907 0.2
Twin Lakes Capital Management, LLC 5925 0.08
Providence Capital Advisors, LLC 200 0
Coppell Advisory Solutions, LLC 149 0
Osaic Holdings Inc 81 0
Sugarloaf Wealth Management, LLC 33 0
Steward Partners Investment Advisory, LLC 6 0



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Geoffrey Paul Kempler B.Sc. Co-Founder & Non-Executive Chairman 207.52k 1955 (69 yıllar)
Dr. David A. Stamler M.D. Chief Executive Officer 613.33k 1961 (63 yıl)
Dr. Rudolph Emile Tanzi Ph.D. Chief Scientific Advisor and Member of Research & Development Advisory Board N/A 1959 (65 yıllar)
Dr. Robert Cherny Head of Research N/A
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. CFO & Company Secretary N/A 1959 (65 yıllar)
Dr. Steven D. Targum M.D. Chief Medical Advisor

Adres: Australia, Melbourne, 350 Collins Street - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://alteritytherapeutics.com